Indian Journal of Pharmacology Home 

RESEARCH ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2021  |  Volume : 53  |  Issue : 4  |  Page : 270--277

Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam

Bushra Hassan Marouf1, Saad Abdulrahman Hussain2, Ziyad Serdar Ali3 
1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaymaniyah, Kurdistan Region, Iraq
2 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al Rafidain University College, Baghdad, Iraq
3 Department of Rheumatology and Orthopedics, Shar Teaching Hospital, Sulaymaniyah, Kurdistan Region, Iraq

Correspondence Address:
Dr. Bushra Hassan Marouf
Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaymaniyah 46001, Kurdistan Region
Iraq

OBJECTIVE: The objective of this study was to analyze the associations between the pro-inflammatory markers with the clinical outcomes of knee osteoarthritis (OA) in patients using resveratrol as an add-on treatment with meloxicam. MATERIALS AND METHODS: This was a double-blind controlled clinical investigation, with 110 eligible patients with OA assigned randomly to receive 15 mg a day meloxicam with either resveratrol 500 mg a day or placebo for 90 days. The standard tools for assessment of pain severity and physical functions were utilized. The tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 in the blood were evaluated. Spearman's correlation coefficient test was used to determine the significance of correlations. RESULTS: The regression analysis to determine the correlation between reductions of the inflammatory biomarkers with the amelioration of the clinical scores showed a nonsignificant weak correlation between these variables. Total clinical scores of each assessment tool that was used “Knee Injury and OA Outcome Score (KOOS) and WOMAC” displayed a weak and nonsignificant correlation with TNF-α, IL-1β blood level. The Spearman's correlation shows a relatively nonsignificant association between IL-6 levels and KOOS, WOMAC, and Visual Analog Scale scores after incorporating resveratrol as an adjuvant with meloxicam for 90 days. CONCLUSION: A weak and nonsignificant correlation between serum biomarkers and the clinical outcomes has been suggested in patients with painful knee OA treated with meloxicam and resveratrol.


How to cite this article:
Marouf BH, Hussain SA, Ali ZS. Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam.Indian J Pharmacol 2021;53:270-277


How to cite this URL:
Marouf BH, Hussain SA, Ali ZS. Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam. Indian J Pharmacol [serial online] 2021 [cited 2021 Sep 17 ];53:270-277
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2021;volume=53;issue=4;spage=270;epage=277;aulast=Marouf;type=0